Literature DB >> 589351

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet.

B F Clarke, I W Campbell.   

Abstract

The clinical effectiveness of metformin was compared with that of chlorpropamide in closely similar groups of 216 non-obese patients recently diagnosed as cases of maturity-onset diabetes that could not be controlled by diet. The incidences of primary and secondary drug failures in each group and the numbers of patients satisfactorily maintained on each of the hypoglycaemic agents throughout the first year proved remarkably similar. In 61 of the successfully treated patients who were studied by crossover to the other drug and observed for a further year the mean blood glucose concentrations at the end of the year were roughly comparable, but the mean weight response was a small loss of 1.5 +/- 3.8 kg with metformin but a gain of 4.6 +/- 3.9 kg with chlorpropamide. Thus for non-obese, maturity-onset diabetics whose disease cannot be controlled by diet and who require oral treatment sulphonylureas and biguanides are equally effective, the choice depending on whether the patient is underweight and the severity of symptoms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 589351      PMCID: PMC1632725          DOI: 10.1136/bmj.2.6102.1576

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  [Further results of diabetes therapy with blood sugar lowering biguanides].

Authors:  H MEHNERT; W SEITZ
Journal:  Munch Med Wochenschr       Date:  1958-11-21

2.  Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics.

Authors:  B F Clarke; I W Campbell
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

3.  Editorials: Statistical problems in clinical trials: the UGDP study revisited.

Authors:  S S Schor
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

4.  Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics.

Authors:  B F Clarke; L J Duncan
Journal:  Lancet       Date:  1968-01-20       Impact factor: 79.321

5.  A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP).

Authors:  H S Seltzer
Journal:  Diabetes       Date:  1972-09       Impact factor: 9.461

6.  Phenformin-associated metabolic acidosis.

Authors:  M Fulop; H D Hoberman
Journal:  Diabetes       Date:  1976-04       Impact factor: 9.461

7.  Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics.

Authors:  M Nattrass; P G Todd; L Hinks; B Lloyd; K G Alberti
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

8.  Influence of phenethylbiguanide on lactic, pyruvic and citric acids in diabetic patients.

Authors:  J W CRAIG; M MILLER; H WOODWARD; E MERIK
Journal:  Diabetes       Date:  1960 May-Jun       Impact factor: 9.461

  8 in total
  18 in total

1.  Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients.

Authors:  L Papoz; D Job; E Eschwege; J P Aboulker; J Cubeau; G Pequignot; M Rathery; G Rosselin
Journal:  Diabetologia       Date:  1978-11       Impact factor: 10.122

2.  Metformin: historical overview.

Authors:  Clifford J Bailey
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 3.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

Review 4.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 5.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 6.  The role of drugs in the treatment of obesity.

Authors:  J G Douglas; J F Munro
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

7.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.

Authors:  L G McAlpine; C H McAlpine; E R Waclawski; A M Storer; J W Kay; B M Frier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Comparative tolerability profiles of oral antidiabetic agents.

Authors:  A J Krentz; R E Ferner; C J Bailey
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 10.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.